1	HIF-stabilization prevents delayed fracture healing				
2	One Sentence Summary: We here provide evidence for a promising preventive approach to enhance bone				
3	regeneration capacities and potentially to overcome compromised bone healing conditions by combining				
4	DFO and MIF – as potent HIF-stabilizers.				
5					
6	Authors: Annemarie Lang <sup>1,2,3</sup> , Sarah Helfmeier <sup>1</sup> , Jonathan Stefanowski <sup>1,2</sup> , Aditi Kuppe <sup>1</sup> , Vikram				
7	Sunkara <sup>4,5</sup> , Moritz Pfeiffenberger <sup>1,2</sup> , Angelique Wolter <sup>1,2</sup> , Alexandra Damerau <sup>1,2</sup> , Shabnam Hemmati-				
8	Sadeghi <sup>1,3,6</sup> , Jochen Ringe <sup>1,3</sup> , Rainer Haag <sup>6</sup> , Anja E. Hauser <sup>1,2</sup> , Max Löhning <sup>1,2</sup> , Carsten Perka <sup>7</sup> , Georg N.				
9 10	Duda <sup>3,7,8</sup> *, Paula Hoff <sup>1,2,3</sup> , Katharina Schmidt-Bleek <sup>3,7,8†</sup> , Timo Gaber <sup>1,2,3†</sup> *, Frank Buttgereit <sup>1,2,3†</sup>				
11	†These authors contributed equally (KSB, TG, FB).				
12	*To whom correspondence should be addressed: timo.gaber@charite.de; georg.duda@charite.de				
13					
14	Affiliations:				
15	<sup>1</sup> Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität				
16	zu Berlin, and Berlin Institute of Health, Department of Rheumatology and Clinical Immunology, Berlin,				
17	Germany				
18	<sup>2</sup> German Rheumatism Research Centre (DRFZ) Berlin, a Leibniz Institute, Berlin, Germany				
19	<sup>3</sup> Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität				
20	zu Berlin, and Berlin Institute of Health, Berlin Institute of Health Center for Regenerative Therapies,				
21	Berlin, Germany				
22	<sup>4</sup> Computational Medicine, Zuse Institute Berlin, Berlin, Germany				
23	<sup>5</sup> Department of Mathematics and Computer Science, Freie Universität Berlin, Berlin, Germany				
24	<sup>6</sup> Institute of Chemistry and Biochemistry, Freie Universität Berlin, Berlin, Germany				
25	<sup>7</sup> Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität				
26	zu Berlin, and Berlin Institute of Health, Center for Musculoskeletal Surgery, Berlin, Germany				
27	<sup>8</sup> Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität				
28	zu Berlin, and Berlin Institute of Health, Julius Wolff Institute, Berlin, Germany				
29					
30					

### 31 Abstract

32 The initial phase of fracture healing decides on success of bone regeneration and is characterized by 33 an inflammatory milieu and low oxygen tension (hypoxia). Negative interference with or prolongation of 34 this fine-tuned initiation phase will ultimately lead to a delayed or incomplete healing such as non-unions 35 which then requires an effective and gentle therapeutic intervention. Common reasons include a 36 dysregulated immune response, immunosuppression or a failure in cellular adaptation to the inflammatory 37 hypoxic milieu of the fracture gap and a reduction in vascularizing capacity by environmental noxious 38 agents (e.g. rheumatoid arthritis, smoking). The hypoxia-inducible factor (HIF)-1 $\alpha$  is responsible for the 39 cellular adaptation to hypoxia, activating angiogenesis and supporting cell attraction and migration to the 40 fracture gap. Here, we hypothesized that stabilizing HIF-1a could be a cost-effective and low-risk 41 prevention strategy of fracture healing disorders. Therefore, we combined a well-known HIF-stabilizer – 42 deferoxamine (DFO) – and a less known HIF-enhancer – macrophage migration inhibitory factor (MIF) – 43 to synergistically induce improved fracture healing. Stabilization of HIF-1 $\alpha$  enhanced calcification and 44 osteogenic differentiation of MSCs in vitro. In vivo, the application of DFO with or without MIF during the 45 initial healing phase accelerated callus mineralization and vessel formation in a clinically relevant mouse-46 osteotomy-model in a compromised healing setting. Our findings provide support for a promising preventive 47 strategy towards bone healing disorders in patients with a higher risk due to e.g. delayed neovascularization 48 by accelerating fracture healing using DFO and MIF to stabilize HIF-1a.

### 50 Introduction

51 Fracture healing combines temporal and spatial fine-tuned and tightly regulated regenerative 52 processes, which lead to a complete restoration of the broken bone without scar formation. However, a 53 minimum of 10 % of patients with fractures suffer from fracture healing disorders such as delayed or 54 incomplete healing (non-unions) leading to immobility, pain, a loss in quality of life, and generate an 55 economic burden for the society (1, 2). While trauma severity and location can determine the healing success 56 (3), several risk factors have been described to potentially impair the fracture healing process such as age 57 and lifestyle including obesity, alcohol abuse, and smoking (4). Of note, smoking is supposed to reduce 58 vessel formation and to stimulate adverse immune reactions (5). Furthermore, chronic inflammatory 59 diseases, such as rheumatoid arthritis (RA) or systemic lupus erythematosus, have been related to fracture 60 healing disorders (6-8). Patients with fracture healing disorders often require several further revision 61 surgeries. Apart from surgical intervention, local delivery of recombinant human (rh)BMP-2 into the 62 fracture gap has been demonstrated in clinical studies to be effective (9, 10). However, several adverse 63 effects in humans strongly restrict the clinical implementation of this approach (11) and alternative strategies 64 or preventive measures are lacking.

65 If a fracture is stabilized such that inter-fragmentary movements can occur, secondary bone healing is initiated leading to bone regeneration via an endochondral ossification process bridging the fracture gap. 66 67 Endochondral bone healing can be divided into five phases: i) initial pro-inflammatory phase, ii) anti-68 inflammatory phase; iii) fibrocartilaginous or soft callus phase; iv) woven bone or hard callus phase; and v) 69 the remodeling phase leading to the bone restitution in form and function according to the mechanical strain 70 (12). The shift from pro- to anti-inflammatory phase is a requirement for angiogenic and pro-osteogenic 71 processes during the initial phase of fracture healing and determine the subsequent regeneration cascades 72 (6, 13). This shift is essential for the initiation of bone reconstruction involving the recruitment of i) 73 monocytes/macrophages, clearing the inflammatory scene and paving the path for revascularization, ii) pre-74 osteoblasts and mesenchymal stromal cells (MSCs) as basic component of bone reconstruction, iii) 75 fibroblasts, which are required for early callus formation and bone matrix formation, and iv) endothelial cells (ECs) for neovascularization (14, 15). Crucial elements for successful bone healing are balanced
control and termination of the pro-inflammatory cascade (16), proper mesenchymal differentiation and
cartilage formation, controlled invasion of vessels (17) as well as a sufficient mechanical stabilization (1821).

80 The hypoxic and inflammatory conditions in the fracture hematoma result from the disruption of 81 vessels, accumulation of inflammatory cells, increased cell death of e.g. erythrocytes and the lack of 82 nutrients, oxygen, high lactate and low pH - a cytotoxic environment which has to be down-regulated to 83 maintain regenerative cells. The oxygen tension within the fracture site is reduced over the first week after 84 trauma being accompanied by a reduction (50%) of blood flow (22-27). Therefore, cellular adaptation 85 mechanisms towards hypoxia are strongly activated – such as the hypoxia inducible factor (HIF) signaling 86 pathway. Both, HIF-1 and HIF-2 are essential for cells to survive hypoxic conditions and to aim at increasing 87 the oxygen supply while reducing oxygen consumption (28). While HIF-1 $\beta$  is constitutively expressed, HIF-88  $1\alpha$  is oxygen-dependently activated and stabilized at less than 5% oxygen (29). HIF-1 $\alpha$  is then translocated 89 to the nucleus, where it heterodimerizes with HIF-1 $\beta$ , binds to its target sequences (hypoxia-responsive 90 elements), and activates genes necessary for cellular hypoxic adaptation (29, 30). Under normoxic 91 conditions, HIF-1 $\alpha$  is hydroxylized by the oxygen- and iron-dependent prolyl-hydroxylase domain (PHD) 92 enzyme/protein and degraded by cellular proteasomes.

93 We have previously examined fracture hematomas obtained from immunologically restricted patients 94 and found reduced osteogenic differentiation due to reduced runt-related transcription factor 2 (RUNX2) 95 expression, exaggerated immune reactions (interleukin IL-8, C-X-C chemokine receptor type 4 CXCR4), 96 and high expression of HIF1A but inadequate expression of target genes (31). We also found higher numbers 97 of monocytes/macrophages, natural killer T (NKT) cells and activated T cells within fracture hematomas of 98 immunologically restricted patients accompanied by higher levels of IL-6, IL-8, tumor necrosis factor 99 (TNF) $\alpha$  and chemokines (e.g. Eotaxin) (32). In order to increase target gene expression, HIF-1 $\alpha$  can be 100 chemically stabilized by different factors, which either inhibit the  $O_2$ -sensing PHD such as deferoxamine 101 (DFO) or directly interfere with the downstream effects after translocation to the nucleus e.g. the 102 macrophage-migration inhibitory factor (MIF) (*33*, *34*).

103 Here, we initially performed a single center retrospective study to investigate the risk factors for 104 fracture healing disorders in a Charité-located patient cohort and to determine the clinical need to 105 preventively support and accelerate fracture healing. Furthermore, we comprehensively systematically 106 reviewed the available literature to delineate the potential of our drafted therapeutic approach of promoting 107 fracture healing using DFO. To this end, we summarized several studies which demonstrated the efficacy 108 of DFO to promote bone fracture healing in a variety of animal models (mouse, rat, rabbit) focusing on 109 different kinds of bone defects. Experimentally, we conducted *in vitro* studies on osteogenesis, which 110 supported the enhancing effect of HIF-1 $\alpha$  stabilization on osteogenic differentiation of MSCs and its 111 counteracting efficacy against e.g. glucocorticoid (GC)-induced inhibition of osteogenesis. Moreover, we 112 tested the combination of MIF and DFO in a mouse-osteotomy-model of compromised bone healing 113 conditions in order to evaluate their preventive capability to counteract delayed bone healing in this 114 clinically relevant model. Thus, our study provides evidence for a promising preventive strategy to 115 accelerate fracture healing by applying potent HIF-stabilizers during initial fracture treatment in patients at 116 risk that may finally help to minimize bone healing disorders.

117

#### 119 **Results**

#### 120 Fracture healing disorders in a single-center patient cohort – A retrospective study

121 Fracture healing disorders are associated with the incidence of several different risk factors e.g. age, 122 gender, fracture location, comorbidities of medications. Therefore, we investigated the main risk factors for 123 fracture healing disorders in a single-center retrospective study at the Center for Musculoskeletal Surgery, 124 Charité-Universitätsmedizin Berlin to get a more precise view of the patient's need for a therapeutic support 125 and acceleration of fracture healing. To this end, we screened data from inpatients treated in the hospital 126 during 2012 (fig. S1). Finally, 79 cases fulfilling inclusion criteria were included in the study (table S1), as 127 well as 178 controls matched for age and fracture location while patients aged < 18 years, having open 128 fractures or metastases close to the fracture location were excluded.

129 First, we performed a descriptive statistical analysis to compare the two groups based on the collected 130 parameters such as body mass index (BMI), gender, alcohol abuse (repeated consumption of alcohol per 131 week), smoking, glucocorticoid and NSAID treatment as well as diagnosed comorbidities as RA, 132 osteoporosis, arterial hypertension and diabetes type 2 (table S2). The average BMI of the two groups was 133 similar. Comparing the control and case group, we found more male patients (53.2% vs. 44.9%) than female 134 patients (46.8% vs. 55.1%) to be affected by fracture healing disorders. Interestingly, alcohol abuse was 135 more often present in the control group as compared to the case group (14.4% vs 2.7%) which was the 136 opposite for smoking (28.1% vs. 37.8%). Regarding medications, a higher number of patients with fracture 137 healing disorders were continuously treated with glucocorticoids (6.3% vs. 1.6%) and NSAIDs (7.6% vs. 138 2.7%) as compared to controls. Although the frequencies of osteoporosis and diabetes type 2 were 139 comparable within both groups, the incidences of RA (6.3% vs. 0.5%) and arterial hypertension (43% vs. 140 33.5%) were higher in the case group. To select potentially relevant factors, an univariable logistic 141 regression was performed (Table 1) using a significance level of 0.15 resulting in the selection of smoking, 142 RA and arterial hypertension for detailed analysis via multivariable logistic regression. Age and gender, 143 parameters well-known to be associated with a poor fracture healing outcome, were additionally included 144 in the subsequent multivariable logistic regression. Statistical analysis using multivariable logistic

- 145 regression showed a high significance for RA (P = 0.028) and a trend for smoking (P = 0.075) to be
- 146 associated with fracture healing disorders such as non-unions.

	Univa	riable	Multivariable			
	Omnibus test	<i>P</i> -value	5	4	3	2
Age	0.597	0.597*	0.118	0.202	-	-
Gender	0.219	0.219*	0.148	-	-	-
BMI	0.212	-				
Alcoholism	0.657	-				
Smoking	0.131	0.129	0.065	0.063	0.048	0.075
Rheumatoid Arthritis	0.006	0.022	0.057	0.047	0.040	0.028
Glucocorticoids	0.725	-				
NSAIDs	0.336	-				
Osteoporosis	0.813	-				
Arterial Hypertension	0.143	0.142	0.085	0.058	0.137	-
Diabetes Type 2	0.908	-				

147 *Table 1: Univariable and multivariable logistic regression.* 

### 148 Deferoxamine as potent target for fracture healing disorders – A systematic literature review

We have previously found that immunologically restricted patients (including e.g. autoimmune disease) show a disturbed response to hypoxia in the fracture hematoma (*31*). Therefore, we hypothesized that HIF-stabilization can accelerate fracture healing in those patients. The inhibition of iron-dependent PHDs by iron chelators or competitors activates HIF-mediated pathways such as angiogenesis and osteogenesis. The iron chelator DFO is well-known from *in vitro* and *in vivo* studies to stabilize HIF (*35*, *36*).

Given this background, we performed a systematic literature review to delineate existing preclinical studies on the effectiveness and efficiency of DFO in fracture healing. In detail, we asked the question whether the local application of DFO in the fracture gap enhanced bone formation ( $\mu$ CT; histomorphometry) during fracture healing in animal models with normal or disturbed fractures of long-bones or *Ossa irregularia* (*mandibula* or *zygomatic arch*). The complete search strategy can be found in figure S2 and S3. 160 We included 20 studies for a descriptive analysis. A meta-analysis was not applicable due to the variability 161 of studies, the variety of models and the information provided (e.g. data values not given; confidential 162 intervals not indicated). Nevertheless, all included studies demonstrated the efficacy of DFO to promote 163 bone fracture healing in a variety of animal models (mouse, rat, rabbit) with different bone defects (Table 164 2). In these studies, DFO was applied in varying doses (in mouse: 20  $\mu$ l of 200  $\mu$ M – 400  $\mu$ M) either once 165 or repetitively by local injection directly into the bone defect/gap or by loading onto a scaffold implanted 166 into the bone defect/gap to counteract a delayed healing or non-union. DFO treatment resulted in a strong 167 promotion of angiogenesis/vessel formation and bone regeneration independent of the species, model and 168 evaluation methods (22-39).

169

Table 2: Systematic literature review on the potential of DFO to accelerate bone formation/healing.


Bone	Model	Application Route & Concentration	Bone/vessel formation	Refs.
aria	Mandibular distraction osteogenesis	Local injection every other day (5 doses); DFO = $200 \mu M$	+++	(37-39)
a irregulı	Mandibular osteotomy or distraction + Radiation	Local injection every other day (5 doses); DFO = 200 µM	+++	(40-46)
$O_{SS_i}$	Zygomatic arch critical-size bone defect	Local injection every other day (> 20 doses); DFO = 200 μM	+++	(47)
	Segmental femur defects (wire)	Application onto scaffold; DFO = $400 \mu M$	+++	(48)
	Tibial non-union model	Application onto scaffold; DFO = 1 mg/kg	+++	(49)
	Femoral drilling hole model	Application onto scaffold; DFO = 1 mg/ml	+++	(36)
es	Tibia cortical drilling + hindlimb unloading	Local injection every other day (2-5 doses); DFO = $200 \mu mol/l$	+++	(50)
ıg bon	Femoral drilling hole + ovariectomy	Application onto scaffold; DFO = $2 \mu g$	+++	(51)
Lor	Distraction osteogenesis in tibia (plate)	Local injection every other day (6 doses); DFO = $200 \mu M$	+++	(35)
	Stabilized femur fracture model (pin)	Local injection every other day (5 doses); DFO = $200 \mu M$	+++	(52)
	Segmental radius bone defects	Application onto scaffold DFO = 2 mM	+++	(53)
	Mid-shaft ulnar defect	Application onto scaffold DFO = 200 µM	+++	(54)
	Long bones Ossa irregularia	Suppose       Mandibular distraction osteogenesis         Mandibular osteotomy or distraction + Radiation         Zygomatic arch critical-size bone defect         Segmental femur defects (wire)         Tibial non-union model         Femoral drilling hole model         Tibia cortical drilling + hindlimb unloading         Femoral drilling hole + ovariectomy         Distraction osteogenesis in tibia (plate)         Stabilized femur fracture model (pin)         Segmental radius bone defects	Proposed OFTMandibular distraction osteogenesisLocal injection every other day (5 doses); DFO = 200 μMMandibular osteotomy or distraction + RadiationLocal injection every other day (5 doses); DFO = 200 μMZygomatic arch critical-size bone defectLocal injection every other day (5 doses); DFO = 200 μMSegmental femur defects (wire)Local injection onto scaffold; DFO = 400 μMTibial non-union modelDFO = 400 μMFemoral drilling hole modelApplication onto scaffold; DFO = 1 mg/kgFemoral drilling hole modelDFO = 1 mg/kgTibia cortical drilling + hindlimb unloadingLocal injection every other day (2-5 doses); DFO = 200 μmOl/lFemoral drilling hole hindlimb unloadingApplication onto scaffold; DFO = 2 μgDistraction osteogenesis in tibia (plate)Local injection every other day (6 doses); DFO = 200 μMStabilized femur fracture model (pin)Local injection every other day (5 doses); DFO = 200 μMSegmental radius bone defectsApplication onto scaffold DFO = 2 mMMid-shaft ulnar defectApplication onto scaffold DFO = 200 μM	PipeopMandibular distraction osteogenesisLocal injection every other day (5 doses); DFO = 200 μM+++Mandibular osteotomy or distraction + RadiationLocal injection every other day (5 doses); DFO = 200 μM+++Zygomatic arch critical-size bone defectLocal injection every other day (> 20 doses); DFO = 200 μM+++Segmental femur defects (wire)Application onto scaffold; DFO = 400 μM+++Tibial non-union modelApplication onto scaffold; DFO = 1 mg/kg+++Femoral drilling hole modelApplication onto scaffold; DFO = 1 mg/nl+++Tibia cortical drilling + hindlimb unloadingLocal injection every other day (2-5 doses); DFO = 200 μmol/l+++Femoral drilling hole houseApplication onto scaffold; DFO = 2 μg+++Femoral drilling hole houseApplication onto scaffold; DFO = 2 μg+++Stabilized femur fracture model (pin)Local injection every other day (6 doses); DFO = 200 μM+++Segmental radius bone defectsApplication onto scaffold DFO = 2 mM+++Mid-shaft ulnar defectApplication onto scaffold DFO = 200 μM+++

170 NZW – New Zealand White rabbits

171 Based on the published data, we concluded that a single injection of DFO might be sufficient to 172 enhance fracture healing under compromised conditions. In addition, we asked if the effect of DFO can be increased by combination with MIF which we have shown to further enhance HIF activity, especially inimmune cells and endothelial cells (55).

## 175 Combining DFO and MIF to enhance in vitro calcification of hMSCs

176 To evaluate the potential of MIF and DFO as enhancer of bone formation in vitro, different 177 concentrations alone and in combination were tested in an osteogenic differentiation assay of bone marrow derived human (h)MSCs. High concentrations of Dexamethasone (Dex;  $10^{-3}$  M) were used as a technical *in* 178 179 *vitro* model to strongly induce delayed calcification while  $10^{-8}$  M Dex was the respective control which is 180 usually included in the osteogenic medium (OM). Large differences in calcification were observed after 4 181 weeks under normoxic conditions and used further titration experiments (fig. S4; fig. S5; Fig. 1). Normoxic 182 conditions represented the inadequate adaptation to hypoxia as mentioned before. Varying concentrations 183 of MIF and DFO alone and in combination were examined for their effect on hMSC calcification. The 184 application of DFO alone showed significant increases in calcification after 4 weeks at 62.5, 125, 250 and 185 500 µM which was also observed at 250 and 500 ng/ml MIF (fig. S5A, B). A double normalization to both controls (10<sup>-3</sup> M and 10<sup>-8</sup> M Dex) revealed that MIF alone did not enhance calcification (Fig. 1A), while 186 187 DFO alone already showed mean increases between 43% - 45.9% (Fig. 1B). The combination of MIF and 188 DFO led to a significant increase in calcium deposition when using 50 ng/ml MIF + 125  $\mu$ M DFO and 100 189 ng/ml MIF + 125 µM DFO with a mean increase of 61.7% to 86.7% for both groups (fig. S5C; Fig. 1C).






191Figure 1: In vitro studies on the effect of MIF and DFO on hMSC calcification. Double normalization of OD values192 $(Dex 10^{-3} M = 0 \%; Dex 10^{-8} M = 100 \%)$  for selected MIF (A), DFO (B) and MIF/DFO (C) concentrations. Asterisks193above and below the bars indicate significant differences as compared to the respective control. Bar graphs show194mean  $\pm$  SEM and individual data points. One sample t-test was used to determine the statistical significance; P-values195are indicated with  $^{\#}P < 0.07; *P < 0.05; **P < 0.01; ***P < 0.001$ . Exemplary images of Alizarin red staining in 96196well are displayed before quantification.

## 197 The effect of MIF and DFO on in vivo bone formation in a delayed healing model

198 Based on the results from the systematic review and our in vitro experiments, we tested MIF and 199 DFO, both alone and in combination in an experimental delayed healing model using a modified mouse-200 osteotomy which results in a local blockage of angiogenesis and results in a delayed bone healing due to 201 insertion of an absorbable bovine Col-I scaffold (ACS) in the osteotomy gap (56). We previously 202 demonstrated that this model features a disturbance in cell invasion, vessel formation and consecutively 203 bone formation when compared to empty-gap controls at 2 and at 3 weeks after osteotomy (56). The 204 osteotomy gap (0.7 mm) was introduced in the femur of 12 weeks old female C57BL/6N mice. A stable 205 fixation of the osteotomized bone was obtained using an external fixator.

206 Bone formation was significantly intensified in the DFO and MIF/DFO treated groups as measured 207 by bone volume fraction at 3 weeks post-osteotomy (Fig. 2A; fig. S6A). We confirmed our finding by 208 histological evaluation quantifying Movat's pentachrome staining (Fig. 2B, C; fig. S6B, C). As a result, we 209 observed increased levels in total mineralized bone tissue in the fracture area and in the fracture gap in all 210 treatments groups after 2 weeks (Fig. 2C). Interestingly, MIF also significantly induced total bone formation 211 especially in the fracture gap at 2 weeks when compared to the corresponding ACS control, while in the 212 other groups mineralized bone formation was more pronounced within the gap (Fig. 2C). Of note, we 213 observed a higher cartilage content in the MIF and DFO group at 2 weeks as compared to the ACS control, 214 while MIF/DFO exhibited similar amounts of cartilage. These differences were not present at 3 weeks, since 215 animals with only ACS show a delayed endochondral ossification (between week 2 and 3; fig. S6C) (56). 216 However, the complete bridging of the fracture gap with cartilage and mineralized bone was observed in 217 50% of DFO and MIF/DFO mice additionally indicating an acceleration of the endochondral ossification 218 process (fig. S7). Interestingly, bridging between cortices was more often observable in the MIF/DFO 219 treated group (50%) (fig. S7). Finally, DFO and MIF/DFO led to a higher recruitment of osterix  $(Osx)^+$ 220 osteoprogenitors/osteoblasts to the fracture gap at 2 weeks (Fig. 2D, E). In addition, Osx<sup>+</sup> cells were more 221 present at day 3 in the DFO group and day 7 in MIF group (fig. S6D). Taken together, these data suggest that both DFO and MIF/DFO accelerated the endochondral ossification process during the fracture healing


in our delayed healing mouse-osteotomy-model.



225 Figure 2: Bone regeneration in a delayed healing model after single dose of MIF or/and DFO. (A) MicroCT 226 quantification at 2 weeks and at 3 weeks post-osteotomy normalized to the median of the ACS group (indicated as 227 dotted line = 1). Bone volume fraction = bone volume/callus volume. Representative 3D microCT reconstructions at 228 week 3. (B) Representative images of Movat's pentachrome staining for each group at week 2. yellow – mineralized 229 bone/scaffold; green – cartilage; magenta – bone marrow. (C) Histomorphometry of Movat's pentachrome staining 230 using ImageJ. Data were normalized to the median of the ACS group (indicated as dotted line = 1). (D) Representative 231 images of immunofluorescence staining of Osterix (Osx) and its quantification. White dotted lines indicate cortices. 232 Schematic bone indicates alignment of images. Scale bars indicate 200µm. Data are shown as box plots with the 233 median as horizontal line, interquartile range as boxes, minimum/maximum as whiskers and individual data points. 234 Wilcoxon signed rank test was applied to determine difference against the ACS control group (hypothetical value = 1) 235 and Kruskal Wallis test with Dunn's multiple comparison test was used to compare groups.  ${}^{\#}P < 0.07$ ;  ${}^{*}P < 0.05$ .

## 236 Vessel formation is increased by HIF-stabilization

237 Revascularization is crucial for bone regeneration, tightly regulated by the microenvironment and appears in two waves at day 7 and day 21 (17, 57).  $CD31^+$  endothelial progenitors enter the fracture gap 238 239 during the initial phase of fracture healing (until day 7) (57). DFO is known to strongly promote 240 revascularization by the induction of vascular endothelial growth factor (VEGF) expression, a target gene 241 of HIF-1 $\alpha$  (34). Therefore, we analyzed the osteotomy site in our delayed healing model for the presence of 242 CD31<sup>+</sup> Emcn<sup>+</sup> vessels. At week 2 and 3, we found significantly more CD31<sup>+</sup> Emcn<sup>+</sup> vessels in the fracture 243 gap of the treatment groups compared to the ACS control group while cell invasion was more pronounced 244 at week 2 and comparable to the ACS control group at week 3 (Fig. 3A-C). Pixel intensity analysis revealed 245 elevated Emcn and CD31 expressions in the DFO and MIF/DFO group at week 2 indicating a higher 246 appearance of CD31<sup>+</sup> and Emcn<sup>+</sup> cells and a higher vascular formation (Fig. 3D-F). Interestingly, MIF alone 247 also induced the expression of CD31 in the fracture gap at week 2 compared to the ACS group (Fig. 3E). 248 However, expression levels were comparable between all groups at week 3. When examining earlier 249 timepoints (day 3 and 7), we observed a comparable appearance of  $CD31^+$  endothelial progenitors in all 250 groups but the DFO group (fig. S8A). In the DFO group, we observed a reduced number of  $CD31^+$ 251 endothelial progenitors at day 7, which was in line with the overall low cell number (DAPI) in the fracture 252 gap during the early stage (fig. S8A). Moreover, immunofluorescence images indicated a pronounced 253 invasion of CD31<sup>+</sup> endothelial progenitors in the region adjacent to the fracture gap (fig. S8B). We conclude 254 from our data that MIF, DFO as well as the combined MIF/DFO enhanced and accelerated revascularization 255 to a considerably higher extent than the corresponding control group as seen at week 2 and 3.



256


257 Figure 3: Revascularization in a delayed healing model under MIF, DFO and MIF/DFO treatment. (A-C) 258 Quantified CD31<sup>+</sup>Emcn<sup>+</sup> stained areas (A) and cell numbers per area (C) normalized to the median of the ACS group 259 (indicated as dotted line = 1) and (B) corresponding representative images for week 2 and 3 (N = 6-8). (D, E) Pixel 260 based intensity analysis of Emcn (D) and CD31 (E) in the fracture gap normalized to the median of the ACS group 261 (indicated as dotted line = 1) and (F) representative images of the combined staining for ACS and MIF/DFO at week 262 2. (N = 6-8). White dotted lines indicate cortices. Schematic bone indicates alignment of images. Scale bars = 200 $\mu$ m. 263 Data are shown as box plots with the median as horizontal line, interquartile range as boxes, minimum/maximum as 264 whiskers and individual data points. Wilcoxon signed rank test was applied to determine difference against the ACS 265 control group (hypothetical value = 1) and Kruskal Wallis test with Dunn's multiple comparison test was used to 266 *compare groups.* \*P < 0.05; \*\*P > 0.01.

## 268 DFO and MIF/DFO lead to enhanced presence of macrophages and TRAP<sup>+</sup> cells

269 Macrophages are essential during fracture healing and we have previously reported the crosstalk 270 between macrophages and vessel especially during the early phase (56, 57). Since the treatment with both 271 DFO and MIF/DFO resulted in an enhanced and accelerated endochondral ossification (Fig. 2) and 272 revascularization (Fig. 3), we further asked whether DFO and MIF/DFO contribute to an increased 273 macrophage invasion. Therefore, we analyzed the osteotomy area for the presence of  $F4/80^+$  cells at 3 days, 274 7 days, 2 weeks and 3 weeks post-surgery. We observed a higher appearance of these cells in the DFO group 275 at day 3 indicating a faster recruitment to the fracture gap, while at day 7 the number was observably reduced 276 as compared to day 3 and the corresponding control (ACS) (Fig. 4A, B). No differences were found between 277 the other groups. Furthermore, we observed a more pronounced presence of tartrate-resistant acid 278 phosphatase (TRAP)<sup>+</sup> cells in the DFO and MIF/DFO group at week 2 than in the ACS group, which was 279 significantly reduced in the MIF group at week 3 when compared to the ACS and DFO group (Fig. 4C, D). 280 TRAP is a well-known marker of osteoclasts but can be also found on activated macrophages (58). In 281 addition, quantifications of the scaffold area after 2 and 3 weeks indicated a significant reduction of the 282 ACS in the osteotomy gap of both the DFO group (at week 2 and 3) and the MIF/DFO group (at week 2) 283 (fig. S9).

Together, these results suggest that both DFO and MIF/DFO promote recruitment of macrophages or local proliferation during the early phase (day 3) and a pronounced expression of TRAP (osteoclast differentiation) thereby supporting the bone regeneration process by providing the space for revascularization.

288






291 Figure 4: Presence of F4/80<sup>+</sup> macrophages and TRAP<sup>+</sup> cells within the fracture gap. (A) Quantified F4/80<sup>+</sup> area in 292 the gap after 3, 7 days and 2, 3 weeks normalized to the median of the ACS group (indicated as dotted line = 1; day 3, 293 7: N = 3-4; week 2, 3: N = 6-8). (B) Representative images for DFO and MIF/DFO at day 3. White dotted lines 294 indicate cortices. Schematic bone indicates alignment of images. (C) Quantification of TRAP<sup>+</sup> area at week 2 and 3 295 normalized to the median of the ACS group (indicated as dotted line = 1) and (D) representative images. Scale bars 296  $= 200 \mu m$ . Data are shown as box plots with the median as horizontal line, interquartile range as boxes, 297 minimum/maximum as whiskers and individual data points. Wilcoxon signed rank test was applied to determine 298 difference against the ACS control group (hypothetical value = 1) and Kruskal Wallis test with Dunn's multiple 299 comparison test was used to compare groups.  ${}^{\#}P < 0.07$ ;  ${}^{*}P < 0.05$ .

## 300 Polyglycerol sulfate-based hydrogels as a potential releasing system for DFO

301 Our results provide evidence for a beneficial effect of DFO in fracture healing and in combination 302 with MIF. In order to delineate a therapeutic option for fracture healing disorders based on HIF-stabilization 303 for e.g. patients with a delayed healing potential due to immunological and/or angiogenic constraints (31, 304 59), we evaluated the potential of an appropriate delivery/release system. Based on the observation that the 305 fracture hematoma obtained from immune-suppressed patients revealed an upregulated inflammatory profile during the initial phase of fracture healing, we tested dendritic polyglycerol sulfate (dPGS)-based 306 307 polyethylene glycol-dicyclooctyne (PEG-DIC) hydrogels, which have been developed to act anti-308 inflammatory (31, 32, 60-62). In addition, we used non-sulfated dendritic polyglycerol (dPG)-based PEG-309 DIC hydrogels as control and potential alternative. Release of DFO from dPG-based hydrogels was slower 310 compared to dPGS-based hydrogels over an observation span of 9 days (Fig. 5A). Supernatants from the 311 release assay were transferred to HEK 293 cells, and protein was collected after 24h. Western blot analysis 312 still indicated the functionality of the released DFO to stabilize HIF-1 $\alpha$  (Fig. 5B). hMSCs were co-cultivated 313 for 2 weeks with the DFO-loaded hydrogels and calcification was analyzed by Alizarin red staining (Fig. 314 5C, D). Unexpectedly, dPGS-based hydrogels seemed to have an inhibitory effect on *in vitro* hMSC 315 calcification independent of DFO loading. Thus, we concluded that the combination of DFO with dPG-316 based hydrogels could be a beneficial approach regarding fracture healing. Moreover, a single dose 317 application/injection proved to be a promising alternative.





319 Figure 5: Release studies of DFO from a polyglycerol sulfate-based hydrogel (dPGS) and a polyglycerol-based 320 *hydrogel (dPG).* (A) DFO release studies from the hydrogels measured over 9 days. Data is shown as mean  $\pm$  SD (N 321 = 6). Two-way ANOVA with Bonferroni posttest was performed to determine significant differences. \*\*\*P < 0.001. 322 (B) Western blot for HIF-1 $\alpha$  and  $\beta$ -actin from HEK 293 cells treated with supernatants from the release experiments. 323 (C, D) Alizarin staining was performed to determine the effect of the hydrogels and the released DFO on hMSC 324 calcification at 2 weeks. (N = 6-11). OM = osteogenic medium/control. Exemplary images of Alizarin red staining in 325 24 well are displayed. Data are shown as box plots with the mean  $\pm$  SEM and individual data points. Wilcoxon signed 326 rank test was applied to determine difference against the OM control group (hypothetical value = 1) and Kruskal 327 Wallis test with Dunn's multiple comparison test was used to compare groups. \*P < 0.05. 328

### 329 Discussion

330 Patients with fracture healing disorders often require further surgeries, experience substantial pain 331 and suffer from prolonged functional impairments. While fracture healing is usually completed within 3 to 332 4 months, non-unions are identified if healing does not succeed after 9 months (no radiological bridging of 333 fragments is visible; (1, 2). Current treatment modalities of non-union include surgical revision, autologous 334 bone grafting or local stimulation of healing by e.g. rhBMP-2 for local delivery into the fracture gap. 335 However, several adverse effects have been reported with BMP-2 and thus clinical usage is strongly 336 restricted (63). Preventive measures for patients potentially at risk do not yet exist. Therefore, strategies that 337 would allow to treat patients with a probable lack in their healing capability early on would be highly 338 desirable. Our single-center retrospective study identified specifically patients with dysregulation of the 339 immune system (e.g. RA) or disturbed capacities in angiogenesis (e.g. smoking) as being at high risk to 340 experience a non-union (**Table 1**), which is in agreement with other reports (6, 64). Induction of regenerative 341 processes within the initial phase of fracture healing depends on an adequate cellular adaptation to the 342 hypoxic microenvironment of the fracture gap (31). Therefore, we hypothesized that stabilization of HIF-343  $1\alpha$  could be an effective approach for the prevention of fracture healing disorders. Based on a systematic 344 literature review, we identified DFO as stimulatory factor in bone regeneration for both a variety of clinical 345 bone healing settings (including mandibular defects and critical size defects) and across various species and 346 models (mouse, rat, rabbit) (Table 2). In vitro, we could demonstrate the effect of a single-dose application 347 of DFO alone and DFO in synergy with MIF to counteract a GC-induced inhibition of calcification during 348 osteogenic differentiation of hMSCs. Finally, we could demonstrate in an *in vivo* proof-of-concept 349 experiment that DFO alone or in synergy with MIF can prevent delayed bone healing in a locally impaired 350 healing model that uses a bovine Col I scaffold in a mouse-osteotomy.

351 Since GCs negatively affect bone metabolism, it is not surprising that GCs have also been reported 352 to negatively affect bone healing (65). Although GCs are essential for osteogenic differentiation at low 353 concentrations, high GC concentrations inhibit osteogenic differentiation and proliferation while favoring 354 adipogenesis (66-71). Therefore, we selected the potent GC dexamethasone to effectively inhibit *in vitro*  calcification of hMSCs as an *in vitro* model for disturbed bone synthesis to test the ability of HIF–stabilizers to re-establish osteogenic differentiation within the present study (Fig. 1). Of note, beside its stabilizing effect on HIF-1 $\alpha$ , DFO directly influences hMSC differentiation via beta-catenin signaling cascades (72). Interestingly, Cobalt(II) chloride, another HIF-stabilizer also increased osteogenic differentiation as recently reported (73). Nevertheless, the counteracting potential of DFO for GC-induced inhibition of osteogenic differentiation as shown in the present study, has not been reported, yet.

However, the ability of MIF, the natural counter-regulator of GC action, to support hypoxia-mediated HIF-1 $\alpha$  stabilization has been shown independently by two groups (*33*, *74*). The *in vitro* findings presented here demonstrate that the impact of MIF alone is not sufficient to overcome the high-dose GC–mediated suppression of osteogenic differentiation. However, MIF – in combination with DFO – synergistically enhanced the counteracting potential of DFO on hMSC calcification (**Fig. 1**). Taken together, DFO and its combination with MIF re-established osteogenic-induced hMSC calcification in a high-dose GC *in vitro* model for disturbed bone synthesis.

368 When analyzing HIF stabilizers/enhancers in an *in vivo* model of delayed healing using a mouse-369 osteotomy-model, we clearly demonstrated that application of DFO alone or in combination with MIF 370 enhanced mineralized callus formation after 14 and 21 days (Fig. 2). This is in line with several previous 371 reports on DFO administered in rat- or mouse-osteotomy-models of Ossa irregularia (mandibula or 372 zygomatic arch) and long bones (femur or tibia) (35-48, 50, 53, 54, 56, 75, 76). All studies showed a strong 373 positive effect of DFO on bone and vessel formation although the application routes and concentrations 374 differed. Most comparable to our present work are the studies of Wan et al. and Yao et al. using the mouse-375 osteotomy-model with medullary pin fixation, but with day-wise repeated local injections of 200 µM DFO 376 (35, 77). In the study presented here, our hypothesis was that a single dose of DFO alone or in combination 377 with MIF is sufficient to accelerate bone formation. Indeed, we could verify our hypothesis by providing 378 evidence for the enhanced mineralized bone formation at later time points (14 and 21 days; Fig. 2). Although 379 the combination with MIF was supposed to further enhance the DFO-mediated enhancement of callus 380 mineralization and bone formation, we assume that the DFO effect alone is strong enough and, therefore, 381 masks the potential additional effect of MIF. However, comparing the histomorphometric results on 382 mineralized bone formation endosteal or intracortical, MIF alone and in combination with DFO showed 383 significantly more mineralized bone in the endosteal compartment after 14 days (Fig. 2) indicating a pivotal 384 role for MIF alone during fracture healing. Ondara et al. described higher expression levels of MIF during 385 the fracture healing process, which has been also described in other regenerative processes such as wound 386 healing (78, 79). MIF deficient mice showed impaired fracture healing caused by a reduced number of 387 osteoclasts and increased osteoid production (80). In our hands, MIF, DFO and MIF/DFO strongly enhanced 388 revascularization much faster than in the control group as shown by the ingrowth of CD31<sup>hi</sup> Emcn<sup>hi</sup> ECs into 389 the osteotomy gap (week 2 vs. 3; Fig. 3). Kusumbe *et al.* described these cells to be part of a bone tissue 390 specific vessel subtype linking angiogenesis and bone formation via Notch and HIF-1  $\alpha$  signaling and 391 located the CD31<sup>hi</sup> Emcn<sup>hi</sup> ECs to the bone surfaces and into the growth plate (81, 82). Moreover, stabilizing 392 HIF by hypoxia or DFO leads to an induction of VEGF expression in different cell types being the major 393 driver of vascularization also during fracture healing (37, 52, 76).

In addition, we observed an accelerated recruitment of macrophages and osteoclast activity based on TRAP activity in the DFO and MIF/DFO group (**Fig. 4**). DFO strongly supported resorption of biomaterial by enhancing osteoclast activity (75), while MIF is well-known to promote osteoclastogenesis by interacting with the RANKL pathway (*80, 83-85*). Furthermore, macrophages play a pivotal role during the whole fracture healing process. Most importantly they promote vascularization and angiogenesis by degrading ECM, which supports the release of angiogenic factors (*86, 87*). Very recently, we have demonstrated the close interconnection between macrophages and vessel formation during fracture healing (*57*).

Finally, we propose dPG as a release system to apply DFO, which may not interfere with the healing process. The advantage of synthetic, biodegradable hydrogels such as dPG is the possibility to adjust the properties of the hydrogel to the specific requirements of the fracture gap. We found that the combination of DFO with dPG could be a promising approach (Fig. 5). However, further studies are needed to optimize the delivery system by further modifications (*88*). Until today, no appropriate delivery system has been approved clinically. 407 In summary, our data provides convinving evidence on the potential of DFO to accelerate bone 408 healing by enhancing mineralization and vessel formation. In addition, MIF alone used at a concentration 409 of 100 ng/ml rather showed inhibitory properties in the regeneration process. The additional effect of MIF 410 on top of the DFO effect was only seen for a few outcomes - e.g. vessel formation. Therefore, it can be 411 supposed that MIF acts concentration-dependent, and further studies on the dosage finding are needed. Here, 412 we showed that the combination of HIF-stabilizers can counteract delayed fracture healing. DFO is 413 approved by the FDA, commercially available (e.g. Desferal® by Novartis AG) and listed on World Health 414 Organization's List of Essential Medicines. We consider DFO as suitable for rapid clinical translation to 415 improve fracture healing and to be used as preventive strategy to avoid bone healing disorders in patients at 416 high risk (e.g. RA and smoking). Therefore, we are currently striving to start a multi-centric confirmatory 417 study with the long-term goal of clinical translation.

#### 418 Limitations

419 In the present study, hMSCs were isolated via migration from the bone marrow although normal 420 protocols recommend density gradient centrifugation. We see increased cell numbers that can be an 421 indication for higher heterogeneity in the following cell culture, which can influence the experimental 422 outcomes. Density gradient centrifugation also has disadvantages such as the loss of smaller cell populations 423 including high proliferative hMSCs. Moreover, there are varying protocols for density gradient 424 centrifugation provided in the literature which does not guarantee reproducibility (89). Furthermore, there 425 is strong evidence in the literature that freshly isolated hMSCs differ from isolated and cultivated hMSCs 426 in their transcriptome and secretome indicating that conclusion from *in vitro* studies should be translated 427 carefully towards in vivo assumptions (90). In the present study, the in vitro studies were rather used as a 428 tool to get insights for further *in vivo* studies than investigating specific pathways.

For the *in vitro* studies on DFO/MIF in our GC-induced delayed calcification assay, all hMSCs were expanded and cultivated in monolayer under normoxic condition which does not parallel the normal bone marrow niche, particularly 3D and hypoxia (*91, 92*). Moreover, a heterogenic population of hMSCs was used for the assays while distinct subpopulations can be influenced differently by the treatments (*93*). In addition, high dexamethasone concentrations were required to mimic significant inhibitory effects of GCs *in vitro*. Those concentrations do not resemble clinically used dosages.

435 Additionally, it should be taken into account that the present study was conducted in mice, and the 436 interpolation to the human is limited. In general, in orthopedic research rodents as well as large animal 437 models are most commonly used. Mice are favored for basic research questions due to the possibility of 438 genetical modifications. In contrast, sheep or pigs are preferred for translational approaches, and rats are 439 more often used for pharmacological interventions and toxicological studies. Most animal species show 440 slight analogies to the human bone macro- and microstructure. Main differences between mice and humans 441 comprise permanent opening of the growth plate in the epiphyses of long bones leading to a lifelong skeletal 442 modeling, the lack of a Haversian system and low cancellous bone content at the epiphyses of long bones 443 (94, 95). Here, a mouse-osteotomy-model was used which does not completely heal within a time period of 444 21 days (osteotomy gap 0.7 mm) in the control group. Thus, an improvement in the healing process can be 445 seen in treated groups. This model only works in female mice since the bone healing process is slower in 446 females than in males (96). However, it is not always possible to determine the exact time frames for every 447 phase during the fracture healing process which makes the interpretation much more complex and might 448 impact especially small differences. This might be a reason why the proposed beneficial effect of MIF is 449 not visible indicating a more technical and methodical challenge rather than a biological non-function.

### 451 Materials and Methods

### 452 Single-center retrospective study

453 In cooperation with the Center for Musculoskeletal Surgery, Charité-Universitätsmedizin Berlin, 454 patient files from patients who were once stationary treated in the hospital during 2012 were screened for 455 ICD-10 classifications M 84.0 (malunion of fracture), M 84.1 (nonunion of fracture) or M 84.2 (delayed 456 union of fracture). Impairment was confirmed by x-rays and patient information as well as patient's history. 457 Ethical approval for the search algorithm and evaluation sheet was provided by the local ethics committee 458 (EA1/349/13). Due to the retrospective character and anonymization, no consent by the included patients 459 was needed. The selected patient files were additionally reviewed by orthopedic experts before inclusion in 460 the study. Therefore, x-rays and patient information as well as history were re-analyzed in detail. Exclusion 461 criteria were age < 18 years, open fractures and metastases close to the fracture location. Collected data 462 included age, sex, birthday, body height and weight, and fracture related patient's history including cause, 463 treatment location and complications. In addition, information on lifestyle (e.g. alcoholism, smoking), 464 comorbidities and medications were gathered. The BMI was calculated based on body height and weight. 465 For statistical analysis, the modelling was performed based on univariable and multivariable logistic 466 regression using SPSS V. 22. The first model was built to determine the potential influence of each variable 467 on the fracture healing outcome. The second model served to identify potential confounding factors and 468 verify the independent contribution of variables to the fracture healing outcome.

#### 469 Systematic literature review

For the systematic literature review the following search terms were used for a Pubmed based search: ("deferoxamine"[Tiab] OR "DFO"[Tiab] OR "DFX" [Tiab] OR "PHD inhibitor"[Tiab]) AND ("fracture"[Tiab] OR "fracture healing"[Tiab] OR "bone healing"[Tiab] OR "bone regeneration"[Tiab] OR "bone formation"[Tiab] OR "osteotomy"[Tiab]) - Filters activated: Publication date to 2019/02/28. Google scholar was searched in addition with the terms: deferoxamine, bone healing, fracture. The detailed search strategy is comprehensively explained in **figure S2** following the PRISMA guidelines and recommendations from Syrf and Syrcle.

## 477 Study design – In vitro and in vivo studies

478 The overall hypothesis of the study was that the local application of MIF/DFO in long bone fractures 479 enhances new bone formation (osteoinduction) and can be used to accelerate fracture healing for the 480 treatment and prevention of fracture healing disorders. For the *in vitro* studies, the endpoints were previously 481 defined by hMSC calcification (Alizarin red staining). For the *in vivo* study the primary endpoint was the 482 bone formation rate (bone volume/total volume) as measured via ex vivo µCT after 2 weeks. Additional 483 endpoints were defined by histomorphometry. Four time points were determined for additional endpoint 484 measurements. The healing outcome was investigated via *ex vivo* µCT and histology at day 14 and 21. Two 485 operated animals were excluded due to infection in the osteotomy gap and one animal was partially excluded 486 (only included for *ex vivo* µCT) due to an oblique fixation.

*In vitro* studies using hMSCs were performed as proof of concept and possibility to determine an adequate concentration of DFO/MIF to be used *in vivo*. hMSCs were used from 4 to 6 different donors (biological replicates) in at least triplicates per experiment and condition (technical replicates). Data was only excluded if donors failed to differentiate as indicated by a positive control that was carried out on every plate. Only hMSCs that passed characterization were used. Calcification was measured via Alizarin red staining as selected prospectively.

For the *in vivo* study, power analysis was performed prior to animal tests (nQuery) to determine the animal number with the results to use a minimum of 6 animals to attain worthwhile results and was provided in detail with the animal experiment application. All analyses were performed blinded for the experimenter by randomly numbering the animals. Animals were randomized for pairs and treatment groups, although animals in one cage were treated with the same substances.

498

#### hMSC cultivation and calcification assay

Bone marrow was collected from patients undergoing total hip replacement at the Center for Musculoskeletal Surgery, Charité-Universitätsmedizin Berlin. Samples were registered and distributed by the "Tissue Harvesting" Core Facility of the Berlin Institute of Health Center for Regenerative Therapies (BCRT) (table S3). Written consents were gathered from all patients. All protocols were approved by the 503 local ethics committee (EA1/012/13) and performed according to the Helsinki Declaration. hMSC isolation, 504 expansion and full characterization (FACS, differentiation) was performed as described previously (56, 97). 505 Expansion was done with DMEM plus GlutaMAX (Thermo Fischer Scientific), 10% FCS (PAA 506 Laboratories), 1% Penicillin-Streptomycin (Thermo Fischer Scientific) at 37°C in 5% CO<sub>2</sub> atmosphere (app. 507 18% O<sub>2</sub>). Cells were used within passage 4-7. For the calcification assay, hMSCs were transferred to a 96-508 well plate with a density of  $1 \times 10^4$  cells/well, cultivated for 24 h and treated with osteogenic medium (OM) 509 consisting of DMEM, 10% FCS, 1% Penicillin-Streptomycin, 10 mM  $\beta$ -glycerophosphate, 10<sup>-8</sup> M 510 dexamethasone water-soluble and 0.1 mM L-ascorbic acid-2-phosphate (Sigma Aldrich). Dexamethasone, 511 Deferoxamine mesylate salt (DFO; Sigma Aldrich) and MIF (lab own production) were supplemented in 512 different concentrations to the medium. Medium was changed weekly. For the release studies OsteoDiff 513 (Miltenyi Biotech) was used supplemented with 1% Penicillin-Streptomycin. For Alizarin red staining cells 514 were fixed with 4% formaldehyde (15 min RT; Carl Roth), washed twice with PBS and stained with 0.5 % 515 Alizarin Red (Sigma Aldrich) in H<sub>2</sub>O<sub>dest</sub> (pH 4) for 10 min at RT followed by 4 washing steps with H<sub>2</sub>O<sub>dest</sub> 516 and application of 10% cetylpyridinium chloride solution (AppliChem) for 30 min at RT. Supernatants were 517 transferred to a new 96 well plate and measured with a Synergy HT plate reader (BioTek Instruments) at a 518 wavelength of 562 nm (reference wavelength 630 nm) for quantification.

519 Animals, housing and osteotomy

Female C57BL/6N mice (12 weeks; body weight 20 - 25 g; Charles River Laboratories) were housed in the Charité animal facility (FEM; semi-sterile - outside the SPF barrier) in pairs in Euro standard Type II clear-transparent plastic cages and kept under obligatory hygiene standards monitored according to the FELASA standards. Nesting material was provided in sufficient amount while pipes and houses were withdrawn after osteotomy to avoid possible entanglement with the used external fixator. Food and water were available ad libitum and the temperature was ( $20 \pm 2$  °C) controlled with a 12 h light/dark period and a humidity of 45-50%. 527 All experiments were carried out with ethical permission according to the policies and principles 528 established by the Animal Welfare Act, the National Institutes of Health Guide for Care and Use of 529 Laboratory Animals, and the National Animal Welfare Guidelines, the ARRIVE guidelines and were 530 approved by the local legal representative animal rights protection authorities (Landesamt für Gesundheit 531 und Soziales Berlin: G 0111/13, 0039/16). Pain management and osteotomy were performed as described 532 in detail previously (56, 57, 98, 99). In short, for analgesia a buprenorphine injection (0.1 mg/kg; Temgesic, 533 RB Pharmaceuticals Limited) s.c. was given prior to the surgery and Tramadol (0.1 mg/ml; Drops, 534 Grünenthal GmbH) was applied with the drinking water for the first 3 post-operative days. Anesthesia was 535 conducted with isoflurane and O<sub>2</sub> supplementation and mice were prepared with eye ointment (Bayer 536 Pharma AG) and clindamycin s.c. (0.02 ml; Ratiopharm GmbH). Osteotomy with an external fixator 537 (MouseExFix, RISystem) was performed at the left femur creating a 0.70 mm osteotomy gap with a Gigli 538 wire saw. The osteotomy gap was filled with PBS-soaked ACS (control; Lyostypt, B. Braun) or MIF and/or 539 DFO solved in PBS applied on the ACS (treatment groups; 100 ng/ml and/or 250 µM, respectively) (56, 540 98). After skin closure, mice received warmed NaCl (0.2 ml) s.c returned to their cages with a prepared nest 541 and an infrared radiator. Animals were euthanized via cervical dislocation after 3, 7, 14 and 21 days in deep 542 anesthesia (no deep pain perception) after intracardial blood collection. Osteotomized femora were collected 543 and either fixed with 4% paraformaldehyde (PFA; Electron Microscopy Sciences) for 6-8 h at 4°C.

### 544

## Ex vivo micro computed tomography ( $\mu CT$ )

545 PFA-fixed femora were treated with an ascending sucrose solution (10%, 20%, 30%) for 24 h, 546 respectively at 4°C. Scanning of 191 slices was performed after removal of the pins and external fixator 547 with an isotropic voxel size of 10.5  $\mu$ m (70 KVp, 114  $\mu$ A; SCANCO  $\mu$ CT Viva 40), aligned scan axis along 548 the diaphyseal axis of the femora and 3D reconstruction and analyses were performed using the provided 549 software package as described previously and applying a fixed global threshold of 240 mg HA/cm<sup>3</sup> for the 550 automatic 3D callus tissue analysis (56, 98). Nomenclature and analysis were conducted in accordance with 551 published recommendations (100).

## 552 Histology and immunofluorescence

553 After µCT scanning, femora were cryo-embedded without decalcification according to the Kawamoto 554 et al. method (101). For Movat's pentachrome staining slices (7 µm) were air dried for 30 min, fixed with 555 4 % PFA for 10 min and washed with H<sub>2</sub>O<sub>dest</sub> for 5 min. The staining procedure was conducted using a 556 protocol already been published (56, 102). The staining results allowed to distinguish between different 557 tissues: mineralized bone or mineralized cartilage appear yellow, hyaline cartilage green, cytoplasm reddish, 558 cell nuclei blue-black and the surrounding muscles are colored in reddish. When combined with Von Kossa 559 staining – the following staining steps were conducted before the Movat's pentachrome staining: 3% (w/v) 560 silver nitrate solution (10 min), washing step with  $H_2O_{dest}$ , sodium carbonate formaldehyde solution (2 min), 561 washing step with tap water, 5% (w/v) sodium thiosulphate solution (5 min), washing step with tap water 562 and H<sub>2</sub>O<sub>dest</sub>. Images were taken with a light microscope (Leica) in a 2.5x magnification and the program 563 Axiovision (Carl Zeiss Microscopy). The Acid Phosphatase, Leukocyte (TRAP) Kit (Sigma Aldrich) was 564 used to stain for TRAP. Manufacturer's instructions were followed, and pictures were taken with a light 565 microscope (Leica).

566 For immunofluorescence staining the following primary antibodies: CD31/PECAM-1 (goat polyclonal unconjugated, AF2628, R&D Systems, 1:100), Emcn (V.7C7 unconjugated, sc-65495, 1:100), 567 F4/80 (Cl:A3-1 unconjugated, MCA497G, 1:400), Osx (rabbit polyclonal, sc-22536-R, 1:200) and 568 569 secondary antibodies (all Thermo Fischer Scientific; 1:500): anti-rat conjugated AF594 (A21209), anti-570 rabbit conjugated AF488 (A21206), anti-rat conjugated AF647 (A21247), anti-goat conjugated AF647 571 (A21447) or anti-goat A568 (A11057) were used. Staining procedure was performed in a wet section as published earlier (56, 57). Pictures were taken with a fluorescence microscope BZ 9000 (Keyence). Image 572 573 analysis was performed with ImageJ (56, 57, 98).

### 574 **DFO release assay**

575 In order to measure the DFO concentration in the supernatant we established the method described 576 by Fielding and Brunström 1964 (*103*). The method is based on the ability of DFO to bind iron and therefore 577 reduces ferric chloride (Fe<sup>3+</sup>) to ferrioxamine (red-brown compound). Measurements were taken including 578 all components (citric acid and Na<sub>2</sub>HPO<sub>4</sub>) and a ferric chloride concentration of 1.5 mg/100 ml at a 579 wavelength of 450 nm (Synergy HT plate reader, BioTek Instruments). Release kinetic experiments were 580 performed in PBS. Hydrogel formation was performed as described in detail before (104). 100 µl of 20% 581 dPG or dPGS were mixed with 10.000 µM DFO and polymerized for 1h at 37°C. For release kinetic and 582 transfer assay 200 µl PBS were added and supernatants were collected every 24h. For transfer assay to HEK 583 293 cells supernatant was collected after 24h and mixed with normal expansion medium (1:10). HEK 293 584 were treated for 24h before collecting protein and performing HIF-1 $\alpha$  western blot as described before (105). 585 For co-cultivation with hMSCs, hydrogels were polymerized in 24-well transwell inserts (Sarstedt; 586 polyethylene terephthalate membrane with 8  $\mu$ m pore size). After polymerization, hydrogels were treated 587 for 12h with osteogenic medium at 37°C for equilibration and transferred to a 24-well plate seeded with 588 hMSCs. Co-cultivation was performed for 14 days with supplementation of osteogenic medium. Alizarin 589 red staining was used to visualize calcification of hMSCs.

### 590 Statistical analysis

591 Statistical analysis was carried out with GraphPad Prism V.8 software. All values from *in vitro* assays 592 were expressed as the mean  $\pm$  SD or SEM when measured in > duplicates and all values from animal 593 experiments are depicted as median  $\pm$  ranges (box and whiskers plot with individual data points). Kruskal 594 Wallis test with Dunn's multiple comparison test and Wilcoxon-signed rank test were applied in case of 595 lack of Gaussian distribution that was tested before via Kolmogorov-Smirnov test. A *p*-value <0.05 was 596 considered as statistically significant. In some cases, statistical trends are indicated with a hashtag (#) when 597 biologically relevant.

## 599 **References**

- D. J. Hak, D. Fitzpatrick, J. A. Bishop, J. L. Marsh, S. Tilp, R. Schnettler, H. Simpson, V. Alt,
   Delayed union and nonunions: epidemiology, clinical issues, and financial aspects. *Injury* 45 Suppl
   2, S3-7 (2014).
- K. D. Hankenson, G. Zmmerman, R. Marcucio, Biological Perspectives of Delayed Fracture Healing. *Injury* 45, S8-S15 (2014).
- 8. R. Zura, Z. Xiong, T. Einhorn, J. T. Watson, R. F. Ostrum, M. J. Prayson, G. J. Della Rocca, S.
  Mehta, T. McKinley, Z. Wang, R. G. Steen, Epidemiology of Fracture Nonunion in 18 Human
  Bones. JAMA Surg 151, e162775 (2016).
- A. H. Karladani, H. Granhed, J. Karrholm, J. Styf, The influence of fracture etiology and type on fracture healing: a review of 104 consecutive tibial shaft fractures. *Arch Orthop Trauma Surg* 121, 325-328 (2001).
- 5. J. A. Scolaro, M. L. Schenker, S. Yannascoli, K. Baldwin, S. Mehta, J. Ahn, Cigarette smoking
  increases complications following fracture: a systematic review. *J Bone Joint Surg Am* 96, 674-681
  (2014).
- 6. L. Claes, S. Recknagel, A. Ignatius, Fracture healing under healthy and inflammatory conditions.
   *Nat Rev Rheumatol* 8, 133-143 (2012).
- 616 7. B. Dominiak, W. Oxberry, P. Chen, Study on a nonhealing fracture from a patient with systemic
  617 lupus erythematosus and its pathogenetic mechanisms. *Ultrastruct Pathol* 29, 107-120 (2005).
- 618 8. B. Stromqvist, Hip fracture in rheumatoid arthritis. *Acta Orthop Scand* 55, 624-628 (1984).
- 619 9. I. Dumic-Cule, M. Peric, L. Kucko, L. Grgurevic, M. Pecina, S. Vukicevic, Bone morphogenetic
  620 proteins in fracture repair. *International Orthopaedics* 42, 2619-2626 (2018).
- 621 10. G. S. Krishnakumar, A. Roffi, D. Reale, E. Kon, G. Filardo, Clinical application of bone morphogenetic proteins for bone healing: a systematic review. *Int Orthop*, (2017).
- M. C. Simmonds, J. V. Brown, M. K. Heirs, J. P. Higgins, R. J. Mannion, M. A. Rodgers, L. A.
  Stewart, Safety and effectiveness of recombinant human bone morphogenetic protein-2 for spinal
  fusion: a meta-analysis of individual-participant data. *Ann Intern Med* 158, 877-889 (2013).
- T. A. Einhorn, L. C. Gerstenfeld, Fracture healing: mechanisms and interventions. *Nat Rev Rheumatol* 11, 45-54 (2015).
- P. Kolar, K. Schmidt-Bleek, H. Schell, T. Gaber, D. Toben, G. Schmidmaier, C. Perka, F. Buttgereit,
  G. N. Duda, The early fracture hematoma and its potential role in fracture healing. *Tissue Eng Part B Rev* 16, 427-434 (2010).
- 631 14. C. J. Kowalczewski, S. Tombyln, D. C. Wasnick, M. R. Hughes, M. D. Ellenburg, M. F. Callahan,
  632 T. L. Smith, M. E. Van Dyke, L. R. Burnett, J. M. Saul, Reduction of ectopic bone growth in
  633 critically-sized rat mandible defects by delivery of rhBMP-2 from kerateine biomaterials.
  634 *Biomaterials* 35, 3220-3228 (2014).
- K. Schmidt-Bleek, A. Petersen, A. Dienelt, C. Schwarz, G. N. Duda, Initiation and early control of
  tissue regeneration bone healing as a model system for tissue regeneration. *Expert opinion on biological therapy* 14, 247-259 (2014).
- K. Schmidt-Bleek, H. Schell, J. Lienau, N. Schulz, P. Hoff, M. Pfaff, G. Schmidt, C. Martin, C.
  Perka, F. Buttgereit, H. D. Volk, G. Duda, Initial immune reaction and angiogenesis in bone healing. *J Tissue Eng Regen Med* 8, 120-130 (2014).
- I7. J. Lienau, K. Schmidt-Bleek, A. Peters, F. Haschke, G. N. Duda, C. Perka, H. J. Bail, N. Schutze,
  F. Jakob, H. Schell, Differential regulation of blood vessel formation between standard and delayed
  bone healing. *J Orthop Res* 27, 1133-1140 (2009).
- B. B. Epari, J. P. Kassi, H. Schell, G. N. Duda, Timely fracture-healing requires optimization of axial fixation stability. *J Bone Joint Surg Am* 89, 1575-1585 (2007).
- D. R. Epari, H. Schell, H. J. Bail, G. N. Duda, Instability prolongs the chondral phase during bone healing in sheep. *Bone* 38, 864-870 (2006).
- J. Lienau, H. Schell, G. N. Duda, P. Seebeck, S. Muchow, H. J. Bail, Initial vascularization and tissue differentiation are influenced by fixation stability. *J Orthop Res* 23, 639-645 (2005).

- P. Strube, U. Sentuerk, T. Riha, K. Kaspar, M. Mueller, G. Kasper, G. Matziolis, G. N. Duda, C.
  Perka, Influence of age and mechanical stability on bone defect healing: age reverses mechanical
  effects. *Bone* 42, 758-764 (2008).
- H. Aro, E. Eerola, A. J. Aho, J. Niinikoski, Tissue oxygen tension in externally stabilized tibial
  fractures in rabbits during normal healing and infection. *J Surg Res* 37, 202-207 (1984).
- D. R. Epari, J. Lienau, H. Schell, F. Witt, G. N. Duda, Pressure, oxygen tension and temperature in the periosteal callus during bone healing--an in vivo study in sheep. *Bone* 43, 734-739 (2008).
- B. Chen, Y. L. Yan, C. Liu, L. Bo, G. F. Li, H. Wang, Y. J. Xu, Therapeutic effect of deferoxamine
  on iron overload-induced inhibition of osteogenesis in a zebrafish model. *Calcif Tissue Int* 94, 353-360 (2014).
- C. Lu, M. Rollins, H. Hou, H. M. Swartz, H. Hopf, T. Miclau, R. S. Marcucio, Tibial fracture decreases oxygen levels at the site of injury. *Iowa Orthop J* 28, 14-21 (2008).
- 662 26. C. Lu, N. Saless, D. Hu, X. Wang, Z. Xing, H. Hou, B. Williams, H. M. Swartz, C. Colnot, T.
  663 Miclau, R. S. Marcucio, Mechanical stability affects angiogenesis during early fracture healing. J
  664 Orthop Trauma 25, 494-499 (2011).
- E. Tøndevold, J. Eriksen, E. Jansen, Observations on long bone medullary pressures in relation to
  arterial PO2, PCO2 and pH in the anaesthetized dog. *Acta Orthop Scand* 50, 645-651 (1979).
- T. Gaber, R. Dziurla, R. Tripmacher, G. R. Burmester, F. Buttgereit, Hypoxia inducible factor (HIF)
  in rheumatology: low O2! See what HIF can do! *Annals of the rheumatic diseases* 64, 971-980
  (2005).
- C. Maes, G. Carmeliet, E. Schipani, Hypoxia-driven pathways in bone development, regeneration
  and disease. *Nature Reviews Rheumatology* 8, 358 (2012).
- b. E. Komatsu, M. Hadjiargyrou, Activation of the transcription factor HIF-1 and its target genes,
  VEGF, HO-1, iNOS, during fracture repair. *Bone* 34, 680-688 (2004).
- P. Hoff, T. Gaber, K. Schmidt-Bleek, U. Senturk, C. L. Tran, K. Blankenstein, S. Lutkecosmann, J.
  Bredahl, H. J. Schuler, P. Simon, G. Wassilew, F. Unterhauser, G. R. Burmester, G. Schmidmaier,
  C. Perka, G. N. Duda, F. Buttgereit, Immunologically restricted patients exhibit a pronounced
  inflammation and inadequate response to hypoxia in fracture hematomas. *Immunol Res* 51, 116-122
  (2011).
- B. Hoff, T. Gaber, C. Strehl, M. Jakstadt, H. Hoff, K. Schmidt-Bleek, A. Lang, E. Rohner, D. Huscher, G. Matziolis, G. R. Burmester, G. Schmidmaier, C. Perka, G. N. Duda, F. Buttgereit, A Pronounced Inflammatory Activity Characterizes the Early Fracture Healing Phase in Immunologically Restricted Patients. *Int J Mol Sci* 18, DOI: 10.3390/ijms18030583 (2017).
- 33. T. Gaber, S. Schellmann, K. B. Erekul, M. Fangradt, K. Tykwinska, M. Hahne, P. Maschmeyer, M.
  Wagegg, C. Stahn, P. Kolar, R. Dziurla, M. Lohning, G. R. Burmester, F. Buttgereit, Macrophage
  migration inhibitory factor counterregulates dexamethasone-mediated suppression of hypoxiainducible factor-1 alpha function and differentially influences human CD4+ T cell proliferation
  under hypoxia. *J Immunol* 186, 764-774 (2011).
- 4. Y. Wang, C. Wan, L. Deng, X. Liu, X. Cao, S. R. Gilbert, M. L. Bouxsein, M. C. Faugere, R. E.
  Guldberg, L. C. Gerstenfeld, V. H. Haase, R. S. Johnson, E. Schipani, T. L. Clemens, The hypoxiainducible factor alpha pathway couples angiogenesis to osteogenesis during skeletal development. *The Journal of clinical investigation* 117, 1616-1626 (2007).
- C. Wan, S. R. Gilbert, Y. Wang, X. Cao, X. Shen, G. Ramaswamy, K. A. Jacobsen, Z. S. Alaql, A.
  W. Eberhardt, L. C. Gerstenfeld, T. A. Einhorn, L. Deng, T. L. Clemens, Activation of the hypoxiainducible factor-1alpha pathway accelerates bone regeneration. *Proc Natl Acad Sci U S A* 105, 686-691 (2008).
- 36. Y. Yan, H. Chen, H. Zhang, C. Guo, K. Yang, K. Chen, R. Cheng, N. Qian, N. Sandler, Y. S. Zhang,
  H. Shen, J. Qi, W. Cui, L. Deng, Vascularized 3D printed scaffolds for promoting bone
  regeneration. *Biomaterials* 190-191, 97-110 (2019).

A. Donneys, A. S. Farberg, C. N. Tchanque-Fossuo, S. S. Deshpande, S. R. Buchman,
Deferoxamine enhances the vascular response of bone regeneration in mandibular distraction
osteogenesis. *Plast Reconstr Surg* 129, 850-856 (2012).

- A. Donneys, D. M. Weiss, S. S. Deshpande, S. Ahsan, C. N. Tchanque-Fossuo, D. Sarhaddi, B.
  Levi, S. A. Goldstein, S. R. Buchman, Localized deferoxamine injection augments vascularity and improves bony union in pathologic fracture healing after radiotherapy. *Bone* 52, 318-325 (2013).
- A. S. Farberg, D. Sarhaddi, A. Donneys, S. S. Deshpande, S. R. Buchman, Deferoxamine enhances
   bone regeneration in mandibular distraction osteogenesis. *Plast Reconstr Surg* 133, 666-671 (2014).
- A. Donneys, S. Ahsan, J. E. Perosky, S. S. Deshpande, C. N. Tchanque-Fossuo, B. Levi, K. M.
  Kozloff, S. R. Buchman, Deferoxamine restores callus size, mineralization, and mechanical strength
  in fracture healing after radiotherapy. *Plast Reconstr Surg* 131, 711e-719e (2013).
- A. Donneys, S. S. Deshpande, C. N. Tchanque-Fossuo, K. L. Johnson, J. T. Blough, J. E. Perosky,
  K. M. Kozloff, P. A. Felice, N. S. Nelson, A. S. Farberg, B. Levi, S. R. Buchman, Deferoxamine
  expedites consolidation during mandibular distraction osteogenesis. *Bone* 55, 384-390 (2013).
- A. Donneys, N. S. Nelson, E. E. Page, S. S. Deshpande, P. A. Felice, C. N. Tchanque-Fossuo, J. P.
  Spiegel, S. R. Buchman, Targeting angiogenesis as a therapeutic means to reinforce osteocyte
  survival and prevent nonunions in the aftermath of radiotherapy. *Head Neck* 37, 1261-1267 (2015).
- A. Donneys, N. S. Nelson, J. E. Perosky, Y. Polyatskaya, J. J. Rodriguez, C. Figueredo, C. A.
  Vasseli, H. C. Ratliff, S. S. Deshpande, K. M. Kozloff, S. R. Buchman, Prevention of radiation-
- vassel, H. C. Rahn, S. S. Deshpande, R. M. Rozion, S. R. Buenman, Trevention of radiationinduced bone pathology through combined pharmacologic cytoprotection and angiogenic
  stimulation. *Bone* 84, 245-252 (2016).
- 44. A. S. Farberg, X. L. Jing, L. A. Monson, A. Donneys, C. N. Tchanque-Fossuo, S. S. Deshpande, S.
  R. Buchman, Deferoxamine reverses radiation induced hypovascularity during bone regeneration and repair in the murine mandible. *Bone* 50, 1184-1187 (2012).
- P. A. Felice, S. Ahsan, A. Donneys, S. S. Deshpande, N. S. Nelson, S. R. Buchman, Deferoxamine administration delivers translational optimization of distraction osteogenesis in the irradiated mandible. *Plast Reconstr Surg* 132, 542e-548e (2013).
- 46. K. M. Urlaub, J. V. Lynn, E. G. Carey, N. S. Nelson, Y. Polyatskaya, A. Donneys, A. C. Mazzoli,
  S. R. Buchman, Histologic Improvements in Irradiated Bone Through Pharmaceutical Intervention
  in Mandibular Distraction Osteogenesis. *J Oral Maxillofac Surg* 76, 2660-2668 (2018).
- 47. S. Guzey, A. Aykan, S. Ozturk, H. Avsever, Y. Karslioglu, A. Ertan, The Effects of Desferroxamine
  on Bone and Bone Graft Healing in Critical-Size Bone Defects. *Ann Plast Surg* 77, 560-568 (2016).
- R. Stewart, J. Goldstein, A. Eberhardt, G. T. Chu, S. Gilbert, Increasing vascularity to improve healing of a segmental defect of the rat femur. *J Orthop Trauma* 25, 472-476 (2011).
- 49. B. S. Grewal, B. Keller, P. Weinhold, L. E. Dahners, Evaluating effects of deferoxamine in a rat tibia critical bone defect model. *J Orthop* 11, 5-9 (2014).
- T. Matsumoto, S. Sato, Stimulating angiogenesis mitigates the unloading-induced reduction in osteogenesis in early-stage bone repair in rats. *Physiological reports* 3, (2015).
- P. Jia, H. Chen, H. Kang, J. Qi, P. Zhao, M. Jiang, L. Guo, Q. Zhou, N. D. Qian, H. B. Zhou, Y. J.
  Xu, Y. Fan, L. F. Deng, Deferoxamine released from poly(lactic-co-glycolic acid) promotes healing
  of osteoporotic bone defect via enhanced angiogenesis and osteogenesis. 104, 2515-2527 (2016).
- X. Shen, C. Wan, G. Ramaswamy, M. Mavalli, Y. Wang, C. L. Duvall, L. F. Deng, R. E. Guldberg,
  A. Eberhart, T. L. Clemens, S. R. Gilbert, Prolyl hydroxylase inhibitors increase neoangiogenesis
  and callus formation following femur fracture in mice. *J Orthop Res* 27, 1298-1305 (2009).
- 53. W. Zhang, G. Li, R. Deng, L. Deng, S. Qiu, New bone formation in a true bone ceramic scaffold loaded with desferrioxamine in the treatment of segmental bone defect: a preliminary study. J Orthop Sci 17, 289-298 (2012).
- 54. J. Drager, J. L. Ramirez-GarciaLuna, A. Kumar, U. Gbureck, E. J. Harvey, J. E. Barralet, (\*)
  Hypoxia Biomimicry to Enhance Monetite Bone Defect Repair. *Tissue Eng Part A* 23, 1372-1381
  (2017).

55. M. Hahne, P. Schumann, M. Mursell, C. Strehl, P. Hoff, F. Buttgereit, T. Gaber, Unraveling the
role of hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha in the adaption process of human
microvascular endothelial cells (HMEC-1) to hypoxia: Redundant HIF-dependent regulation of
macrophage migration inhibitory factor. *Microvasc Res* 116, 34-44 (2018).

- A. Lang, M. Kirchner, J. Stefanowski, M. Durst, M. C. Weber, M. Pfeiffenberger, A. Damerau, A.
  E. Hauser, P. Hoff, G. N. Duda, F. Buttgereit, K. Schmidt-Bleek, T. Gaber, Collagen I-based scaffolds negatively impact fracture healing in a mouse-osteotomy-model although used routinely in research and clinical application. *Acta Biomater* 86, 171-184 (2019).
- J. Stefanowski, A. Lang, A. Rauch, L. Aulich, M. Köhler, A. F. Fiedler, F. Buttgereit, K. SchmidtBleek, G. N. Duda, T. Gaber, R. A. Niesner, A. E. Hauser, Spatial Distribution of Macrophages
  During Callus Formation and Maturation Reveals Close Crosstalk Between Macrophages and
  Newly Forming Vessels. *Frontiers in Immunology* 10, (2019).
- 58. J. How, J. R. Brown, S. Saylor, D. L. Rimm, Macrophage expression of tartrate-resistant acid
  phosphatase as a prognostic indicator in colon cancer. *Histochemistry and cell biology* 142, 195204 (2014).
- 59. C. H. Bucher, C. Schlundt, D. Wulsten, F. A. Sass, S. Wendler, A. Ellinghaus, T. Thiele, R.
  Seemann, B. M. Willie, H. D. Volk, G. N. Duda, K. Schmidt-Bleek, Experience in the Adaptive Immunity Impacts Bone Homeostasis, Remodeling, and Healing. *Front Immunol* 10, 797 (2019).
- K. Licha, P. Welker, M. Weinhart, N. Wegner, S. Kern, S. Reichert, I. Gemeinhardt, C. Weissbach,
  B. Ebert, R. Haag, M. Schirner, Fluorescence Imaging with Multifunctional Polyglycerol Sulfates:
  Novel Polymeric near-IR Probes Targeting Inflammation. *Bioconjugate Chemistry* 22, 2453-2460
  (2011).
- T. Schneider, P. Welker, K. Licha, R. Haag, G. Schulze-Tanzil, Influence of dendritic polyglycerol sulfates on knee osteoarthritis: an experimental study in the rat osteoarthritis model. *BMC Musculoskeletal Disorders* 16, 387 (2015).
- H. Türk, R. Haag, S. Alban, Dendritic Polyglycerol Sulfates as New Heparin Analogues and Potent Inhibitors of the Complement System. *Bioconjugate Chemistry* 15, 162-167 (2004).
- E. A. Barcak, M. J. Beebe, Bone Morphogenetic Protein: Is There Still a Role in Orthopedic Trauma in 2017? *Orthop Clin North Am* 48, 301-309 (2017).
- R. K. Hernandez, T. P. Do, C. W. Critchlow, R. E. Dent, S. S. Jick, Patient-related risk factors for fracture-healing complications in the United Kingdom General Practice Research Database. *Acta Orthop* 83, 653-660 (2012).
- 781 65. Y. Hachemi, A. E. Rapp, A.-K. Picke, G. Weidinger, A. Ignatius, J. Tuckermann, Molecular mechanisms of glucocorticoids on skeleton and bone regeneration after fracture. *Journal of molecular endocrinology* 61, R75-R90 (2018).
- 66. I. Carcamo-Orive, A. Gaztelumendi, J. Delgado, N. Tejados, A. Dorronsoro, J. Fernandez-Rueda,
  D. J. Pennington, C. Trigueros, Regulation of human bone marrow stromal cell proliferation and
  differentiation capacity by glucocorticoid receptor and AP-1 crosstalk. *J Bone Miner Res* 25, 21152125 (2010).
- P. L. Chang, H. C. Blair, X. Zhao, Y. W. Chien, D. Chen, A. B. Tilden, Z. Chang, X. Cao, O. M.
  Faye-Petersen, P. Hicks, Comparison of fetal and adult marrow stromal cells in osteogenesis with and without glucocorticoids. *Connect Tissue Res* 47, 67-76 (2006).
- 68. C. D. Hoemann, H. El-Gabalawy, M. D. McKee, In vitro osteogenesis assays: influence of the primary cell source on alkaline phosphatase activity and mineralization. *Pathol Biol (Paris)* 57, 318-323 (2009).
- 69. I. H. Song, A. I. Caplan, J. E. Dennis, In vitro dexamethasone pretreatment enhances bone formation
  of human mesenchymal stem cells in vivo. *J Orthop Res* 27, 916-921 (2009).
- 796 70. G. Tan, P. D. Kang, F. X. Pei, Glucocorticoids affect the metabolism of bone marrow stromal cells and lead to osteonecrosis of the femoral head: a review. *Chin Med J (Engl)* 125, 134-139 (2012).
- 798 71. S. Walsh, G. R. Jordan, C. Jefferiss, K. Stewart, J. N. Beresford, High concentrations of dexamethasone suppress the proliferation but not the differentiation or further maturation of human

800osteoblast precursors in vitro: relevance to glucocorticoid-induced osteoporosis. Rheumatology801(Oxford) 40, 74-83 (2001).


- Z. H. Qu, X. L. Zhang, T. T. Tang, K. R. Dai, Promotion of osteogenesis through beta-catenin signaling by desferrioxamine. *Biochem Biophys Res Commun* **370**, 332-337 (2008).
- X. Yu, Q. Wan, G. Cheng, X. Cheng, J. Zhang, J. L. Pathak, Z. Li, CoCl2, a mimic of hypoxia,
  enhances bone marrow mesenchymal stem cells migration and osteogenic differentiation via
  STAT3 signaling pathway. *Cell Biol Int* 42, 1321-1329 (2018).
- M. Winner, A. C. Koong, B. E. Rendon, W. Zundel, R. A. Mitchell, Amplification of tumor hypoxic responses by macrophage migration inhibitory factor-dependent hypoxia-inducible factor stabilization. *Cancer Res* 67, 186-193 (2007).
- 75. J. Drager, Z. Sheikh, Y. L. Zhang, E. J. Harvey, J. E. Barralet, Local delivery of iron chelators reduces in vivo remodeling of a calcium phosphate bone graft substitute. *Acta Biomater* 42, 411-419 (2016).
- 813 76. B. P. Hertzberg, J. B. Holt, R. D. Graff, S. R. Gilbert, L. E. Dahners, An evaluation of carrier agents
  814 for desferoxamine, an up-regulator of vascular endothelial growth factor. *J Biomater Appl* 27, 1046815 1054 (2013).
- 816 77. Q. Yao, Y. Liu, J. Tao, K. M. Baumgarten, H. Sun, Hypoxia-Mimicking Nanofibrous Scaffolds
  817 Promote Endogenous Bone Regeneration. *ACS Appl Mater Interfaces* 8, 32450-32459 (2016).
- 818 78. S. Onodera, J. Nishihira, M. Yamazaki, T. Ishibashi, A. Minami, Increased expression of
  819 macrophage migration inhibitory factor during fracture healing in rats. *Histochem Cell Biol* 121,
  820 209-217 (2004).
- 821 79. S. C. Gilliver, E. Emmerson, J. Bernhagen, M. J. Hardman, MIF: a key player in cutaneous biology
  822 and wound healing. *Exp Dermatol* 20, 1-6 (2011).
- 80. T. Kobayashi, S. Onodera, E. Kondo, H. Tohyama, H. Fujiki, A. Yokoyama, K. Yasuda, Impaired
  fracture healing in macrophage migration inhibitory factor-deficient mice. *Osteoporos Int* 22, 19551965 (2011).
- 826 81. A. P. Kusumbe, S. K. Ramasamy, R. H. Adams, Coupling of angiogenesis and osteogenesis by a specific vessel subtype in bone. *Nature* 507, 323-328 (2014).
- 828 82. S. K. Ramasamy, A. P. Kusumbe, L. Wang, R. H. Adams, Endothelial Notch activity promotes angiogenesis and osteogenesis in bone. *Nature* 507, 376-380 (2014).
- 830
  83. R. Gu, L. L. Santos, D. Ngo, H. Fan, P. P. Singh, G. Fingerle-Rowson, R. Bucala, J. Xu, J. M.
  831
  832
  832
  834
  835
  835
  836
  836
  837
  837
  838
  838
  839
  839
  839
  830
  830
  830
  830
  830
  831
  831
  831
  832
  832
  832
  833
  834
  835
  835
  835
  836
  836
  837
  837
  838
  838
  838
  839
  839
  839
  830
  830
  830
  830
  830
  831
  831
  832
  832
  832
  832
  832
  832
  832
  832
  832
  832
  832
  832
  832
  832
  832
  832
  832
  833
  834
  834
  835
  835
  835
  835
  835
  835
  835
  835
  835
  835
  835
  835
  835
  835
  835
  835
  835
  835
  835
  835
  835
  835
  835
  835
  835
  835
  835
  835
  835
  835
  835
  835
  835
  835
  835
  835
  835
  835
  835
  835
  835
  835
  835
  835
  835
  835
  835
  835
  835
  835
  835
  835
  835
  835
  835
  835
  835
  835
  835
  835
  835
  835
  835
  835
  835
  835
  835
  835
  835
  835
  835
  835
  835
  835
  835
  835
  835
  835
  835
  835</l
- 833 84. S. H. Mun, H. Y. Won, P. Hernandez, H. L. Aguila, S. K. Lee, Deletion of CD74, a putative MIF
  receptor, in mice enhances osteoclastogenesis and decreases bone mass. *J Bone Miner Res* 28, 948959 (2013).
- 836
  85. L. Zheng, J. Gao, K. Jin, Z. Chen, W. Yu, K. Zhu, W. Huang, F. Liu, L. Mei, C. Lou, D. He,
  Macrophage migration inhibitory factor (MIF) inhibitor 4-IPP suppresses osteoclast formation and
  promotes osteoblast differentiation through the inhibition of the NF-kappaB signaling pathway. *Faseb j*, fj201802364RR (2019).
- 86. R. P. Pirraco, R. L. Reis, A. P. Marques, Effect of monocytes/macrophages on the early osteogenic differentiation of hBMSCs. *J Tissue Eng Regen Med* 7, 392-400 (2013).
- 87. L. J. Raggatt, M. E. Wullschleger, K. A. Alexander, A. C. Wu, S. M. Millard, S. Kaur, M. L.
  843 Maugham, L. S. Gregory, R. Steck, A. R. Pettit, Fracture healing via periosteal callus formation 844 requires macrophages for both initiation and progression of early endochondral ossification. *Am J* 845 *Pathol* 184, 3192-3204 (2014).
- 846 88. X. Bai, M. Gao, S. Syed, J. Zhuang, X. Xu, X.-Q. Zhang, Bioactive hydrogels for bone regeneration.
  847 *Bioactive materials* 3, 401-417 (2018).
- 848
   89. N. Y. Naung, S. Suttapreyasri, S. Kamolmatyakul, T. Nuntanaranont, Comparative study of different centrifugation protocols for a density gradient separation media in isolation of

850 osteoprogenitors from bone marrow aspirate. *Journal of oral biology and craniofacial research* 4,
851 160-168 (2014).

- B52 90. H. Li, R. Ghazanfari, D. Zacharaki, H. C. Lim, S. Scheding, Isolation and characterization of primary bone marrow mesenchymal stromal cells. *Ann N Y Acad Sci* 1370, 109-118 (2016).
- A. Papadimitropoulos, E. Piccinini, S. Brachat, A. Braccini, D. Wendt, A. Barbero, C. Jacobi, I.
  Martin, Expansion of human mesenchymal stromal cells from fresh bone marrow in a 3D scaffoldbased system under direct perfusion. *PLoS One* 9, e102359 (2014).
- Y. Zhou, H. Chen, H. Li, Y. Wu, 3D culture increases pluripotent gene expression in mesenchymal stem cells through relaxation of cytoskeleton tension. *Journal of cellular and molecular medicine* 21, 1073-1084 (2017).
- H. Oshina, S. Sotome, T. Yoshii, I. Torigoe, Y. Sugata, H. Maehara, E. Marukawa, K. Omura, K.
  Shinomiya, Effects of continuous dexamethasone treatment on differentiation capabilities of bone marrow-derived mesenchymal cells. *Bone* 41, 575-583 (2007).
- P. S. Gomes, M. H. Fernandes, Rodent models in bone-related research: the relevance of calvarial defects in the assessment of bone regeneration strategies. *Lab Anim* 45, 14-24 (2011).
- M. Peric, I. Dumic-Cule, D. Grcevic, M. Matijasic, D. Verbanac, R. Paul, L. Grgurevic, V. Trkulja,
  C. M. Bagi, S. Vukicevic, The rational use of animal models in the evaluation of novel bone
  regenerative therapies. *Bone* 70, 73-86 (2015).
- M. Mehta, H. Schell, C. Schwarz, A. Peters, K. Schmidt-Bleek, A. Ellinghaus, H. J. Bail, G. N.
  Duda, J. Lienau, A 5-mm femoral defect in female but not in male rats leads to a reproducible atrophic non-union. *Arch Orthop Trauma Surg* 131, 121-129 (2011).
- 871 97. T. Gaber, A. C. K. Brinkman, J. Pienczikowski, K. Diesing, A. Damerau, M. Pfeiffenberger, A.
  872 Lang, S. Ohrndorf, G. R. Burmester, F. Buttgereit, P. Hoff, Impact of Janus Kinase Inhibition with
  873 Tofacitinib on Fundamental Processes of Bone Healing. *Int J Mol Sci* 21, (2020).
- P. Jirkof, M. Durst, R. Klopfleisch, R. Palme, C. Thone-Reineke, F. Buttgereit, K. Schmidt-Bleek,
  A. Lang, Administration of Tramadol or Buprenorphine via the drinking water for post-operative
  analgesia in a mouse-osteotomy model. *Sci Rep* 9, DOI: 10.1038/s41598-41019-47186-41595
  (2019).
- A. Lang, A. Schulz, A. Ellinghaus, K. Schmidt-Bleek, Osteotomy models the current status on pain scoring and management in small rodents. *Lab Anim* 50, 433-441 (2016).
- M. L. Bouxsein, S. K. Boyd, B. A. Christiansen, R. E. Guldberg, K. J. Jepsen, R. Muller, Guidelines
   for assessment of bone microstructure in rodents using micro-computed tomography. *J Bone Miner Res* 25, 1468-1486 (2010).
- 101. T. Kawamoto, K. Kawamoto, Preparation of thin frozen sections from nonfixed and undecalcified
  hard tissues using Kawamot's film method (2012). *Methods Mol Biol* 1130, 149-164 (2014).
- 102. C. Schlundt, T. El Khassawna, A. Serra, A. Dienelt, S. Wendler, H. Schell, N. van Rooijen, A.
  Radbruch, R. Lucius, S. Hartmann, G. N. Duda, K. Schmidt-Bleek, Macrophages in bone fracture
  healing: Their essential role in endochondral ossification. *Bone* 106, 78-89 (2015).
- I03. J. Fielding, M. Brunstroem, ESTIMATION OF FERRIOXAMINE AND DESFERRIOXAMINE
  IN URINE. J Clin Pathol 17, 395-398 (1964).
- 890 104. S. Hemmati-Sadeghi, P. Dey, J. Ringe, R. Haag, M. Sittinger, T. Dehne, Biomimetic sulfated
  891 polyethylene glycol hydrogel inhibits proteoglycan loss and tumor necrosis factor-α-induced
  892 expression pattern in an osteoarthritis in vitro model. *Journal of Biomedical Materials Research*893 *Part B: Applied Biomaterials* 107, 490-500 (2019).
- M. Wagegg, T. Gaber, F. L. Lohanatha, M. Hahne, C. Strehl, M. Fangradt, C. L. Tran, K.
  Schonbeck, P. Hoff, A. Ode, C. Perka, G. N. Duda, F. Buttgereit, Hypoxia promotes osteogenesis
  but suppresses adipogenesis of human mesenchymal stromal cells in a hypoxia-inducible factor-1
  dependent manner. *PLoS One* 7, e46483 (2012).
- 898

899 Acknowledgments: The authors would like to thank Gabriela May, Manuela Jakstadt, Gabriela 900 Korus, Marie-Christin Weber and Mario Thiele for excellent technical assistance. Additionally, we like to 901 acknowledge Peter Schlattmann (University of Jena, Germany) for supporting logistic regression analysis. 902 Moreover, Anastasia Rakow and Paul Simon served as orthopedic expert team to re-analyze the cases 903 included in the retrospective study. FACS analyses were performed together with the Core Facility at the 904 German Rheumatism Research Centre. Bone-marrow was provided from the "Tissue Harvesting" Core 905 Facility of the BCRT. This study is a part of Annemarie Lang's PhD thesis as published under 906 https://refubium.fu-berlin.de/handle/fub188/26365. The retrospective study was performed within the 907 doctoral dissertation of Sara Fügener (now Helfmeier) https://refubium.fu-908 berlin.de/handle/fub188/3611?show=full. Funding: This study was financially supported by the Berlin 909 Brandenburg Center for Regenerative Therapies (BCRT) and the Berlin Brandenburg School for 910 Regenerative Therapies (BSRT). The work of Timo Gaber was funded by the Deutsche 911 Forschungsgemeinschaft (DFG; no. 353142848). Some data were taken during a refinement study on the 912 pain management in the mouse osteotomy model that was financed by the federal ministry for risk 913 assessment (BfR and Bf3R) in Berlin ("RefineMOMo"; 1328-542). The work of Anja E. Hauser was funded 914 by DFG FOR2165 (HA5354/6-2 to A.E.H.). Author contributions: : K.S.B., G.N.D., M.L., T.G. and F.B. 915 conceived and supervised the research. S.H., A.L., P.H., C.P. and F.B. designed the retrospective study, 916 performed data collection and quality control and performed analysis. A.L., K.S.B. an T.G. designed and 917 performed in vitro and animal experiments. A.L., J.S., A.K., V.S., A.W. A.D. and M.P. performed analysis. 918 A.L., T.G., J.R., S.H.-S., R.H. planned, supervised or performed release assays. A.L., F.B., T.G. and K.S.B. 919 wrote the paper. A.E.H., G.N.D. and M. L. revised manuscript. Competing interests: Authors confirm no 920 competing interest. Data and materials availability: All data associated with this study are present in the 921 paper or the Supplementary Materials.

922



**Exclusion criteria** 

age < 18 years

open fractures metastases close to fracture location



929 Figure S6: Search strategy of the retrospective study including inclusion and exclusion criteria.

930

931	Table S1: Detailed characterization of the 79 included case	es.
-----	---	-----

Charité-Universitätsmedizin

Berlin

	Total number	in %			
ICD-10 classification					
M 84.0	12	15.2			
M 84.1	61	77.2			
M 84.2	6	7.6			
Fracture localisation					
Humerus	15	19.0			
Radius, ulna	12	15.2			
Femur	20	25.3			
Tibia, fibula	11	13.9			
Clavicle	7	8.9			
Scaphoid	5	6.3			
Vertebrae	4	5.1			
Os sacrum	1	1.3			
Patella	1	1.3			
Metatarsal	3	3.8			

information and

history

79 cases

included

14 cases

187 controls

(matched for age &

fracture site)


## 933 Table S2: Descriptive analysis.

	Controls in %	Cases in %
Age		
18 - 39	26.2	30.4
40 - 59	36.9	34.2
> 60	36.9	35.4
Gender		
male	44.9	53.2
female	55.1	46.8
BMI		
< 20	9.9	6.5
20 - 25	40.7	41.6
> 25	49.4	51.9
Alcohol abuse		
no	85.6	97.3
yes	14.4	2.7
Smoking		
no	71.9	62.2
yes	28.1	37.8
Glucocorticoids		
no	97.3	93.7
continuously	1.6	6.3
temporarly	1.1	0
NSAIDs		
no	84.5	86.1
continuously	2.7	7.6
ASS-100 mg	12.8	6.3
Rheumatoid Arthritis		
no	99.5	93.7
yes	0.5	6.3
Osteoporosis		
no	90.8	89.9
yes	9.5	10.1
Arterial Hypertension		
no	66.5	57.0
yes	33.5	43.0
Diabetes Type 2		
no	88.1	88.6
yes	11.9	11.4

934


# 936 2. Systematic literature review – Search strategy

937




- 939 Figure S7: Search strategy of the systematic literature review in accordance with the PRISMA
- 940 guidelines and recommendations from Syrf and Syrcle.

941




943 Figure S8: Flow diagram of the systematic literature review resulting in the inclusion of 20 studies.

# **3.** *In vitro* and *in vivo* studies – Additional data



948Figure S9: In vitro model pre-testing. Determination of the conditions and testing period of the949calcification assay for further titration experiments under normoxic conditions (N = 4-6; > triplicates). Bar950graphs show mean ± SEM and individual data points.




952

953 Figure S10: Titration of different MIF and DFO concentrations alone (A, B) and in combination (C).

hMSCs were cultivated under normoxia for 4 weeks with addition of osteogenic medium (OM). OD values


955 gained after Alizarin red staining were normalized to Dex  $10^{-3}$  M (N = 4-6; > triplicates). Bar graphs show

956 *mean*  $\pm$  *SEM and individual data points. One sample t-test was used to determine statistical significance* 957 *towards the hypothetical value of 1. p-values are indicated with*  $^{\#}P < 0.07$ ;  $^{*}P < 0.05$ .



958

959 Figure S11: Bone regeneration in a delayed healing model after single dose of MIF or/and DFO additional data. (A) MicroCT quantification of total volume and bone volume at 2 weeks and at 3 weeks 960 961 post-osteotomy normalized to the median of the ACS group (indicated as dotted line = 1). (B) Representative 962 images of Movat's pentachrome staining for each treatment group. yellow- mineralized bone/scaffold; green – cartilage; magenta – bone marrow. Representative images for <sup>#</sup>MIF/DFO, 3 weeks of von Kossa 963 964 combined with Movat's pentachrome staining to show the distinction between mineralized bone and 965 residual scaffold. (C) Histomorphometry of Movat's pentachrome staining using ImageJ. Data were 966 normalized to the median of the ACS group (indicated as dotted line = 1). (D) Quantification of Osx staining 967 at 3, 7 days and 3 weeks. Data are shown as box plots with the median as horizontal line, interquartile 968 range as boxes, minimum/maximum as whiskers and individual data points. Wilcoxon signed rank test was 969 applied to determine difference against the ACS control group (hypothetical value = 1) and Kruskal Wallis test with Dunn's multiple comparison test was used to compare groups.  ${}^{\#}P < 0.07$ ;  ${}^{*}P < 0.05$ . 970



972

Figure S12: Results of two qualitative scores that were performed with all slides (Movat's pentachrome staining) by 3 independent experimenters. Score criteria are specified in the graphs. Mean score I focused in the intracortical area indicating a bridging between the cortices. Mean score II focus in the filling of the fracture gap/ bone marrow area between cortices. The qualitative score was aimed to underline subjective

977 *findings and the quantification via histomorphometry.* 

978

979







Figure S13: Revascularization in a delayed healing model under MIF, DFO and MIF/DFO treatment – 981 982 additional data. (A) Quantification  $CD31^+$  stained areas and cell numbers per area normalized to the 983 median of the ACS group (indicated as dotted line = 1) and (B) corresponding representative images for 984 day 3 and 7 (N = 3-4). White dotted lines indicate cortices. Schematic bone indicates alignment of images. 985 Scale bars =  $200\mu m$ . Data are shown as box plots with the median as horizontal line, interquartile range 986 as boxes, minimum/maximum as whiskers and individual data points. Wilcoxon signed rank test was applied 987 to determine difference against the ACS control group (hypothetical value = 1) and Kruskal Wallis test with 988 Dunn's multiple comparison test was used to compare groups.

989



992Figure S14: Presence of F4/80+ macrophages and TRAP+ cells within the fracture gap – additional data.993(A) Quantified total scaffold areas and (B) in the gap after 2 and 3 weeks normalized to the median of the994ACS group (indicated as dotted line = 1). (N = 6-8). Data are shown as box plots with the median as995horizontal line, interquartile range as boxes, minimum/maximum as whiskers and individual data points.996Wilcoxon signed rank test was applied to determine difference against the ACS control group (hypothetical997value = 1) and Kruskal Wallis test with Dunn's multiple comparison test was used to compare groups. \*P998< 0.05.</td>

## 1000 Table S3: List of hMSCs that were used in the study.

Donor	Age	Gender	Cultivation condition	Characterization	Experiments
1	52	female			
2	77	female	Expansion in normal medium:		
3	70	female	DMEM plus GlutaMAX, 10% FCS,		
4	76	male	1% Penicillin-Streptomycin		
5	73	female	Osteogenic medium:		
6	69	female	DMEM plus GlutaMAX, 10% FCS,		MIF/DFO titration
7	48	male	1% Penicillin-Streptomycin,		
8	75	female	10 mM $\beta$ -glycerophosphate,		
9	82	male	10-8 M dexamethasone, 0.1 mM L-	+ plastic adherent	
10	56	female	ascorbic acid-2-phosphate	+ osteogenic/adipogenic	
11	66	male		differentiation	
12	69	female		+ CD13, CD44, CD90, CD105	
13	57	male	<b>F</b> · · · · · · ·	- CD45, CD14, CD19	
14	84	female	Expansion in normal medium: DMEM plus GlutaMAX, 20%		
15	65	male	StemMACS, 10% (v/v) FCS, 1%		
16	71	female	Penicillin-Streptomycin		
17	75	female			DFO release experiments
19	78	male	<u>Osteogenic medium:</u> StemMACS OsteoDiff Medium, %		
20	61	female	Penicillin-Streptomycin		
21	63	male			
22	77	male			
23	63	male			